Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Growth of In-Situ Hybridization Testing Exceeds Other Technologies

By LabMedica International staff writers
Posted on 26 Apr 2010
In situ hybridization tests (ISH), which are probes for specific DNA sequences performed on portions of tumor tissue, have become one of the fastest growing market segments in laboratory medicine, showing 8% sales growth per year, according to a recent market report. More...


With new enhancements the technology will continue to drive revenues for Abbott Laboratories (Abbott Park, IL, USA), Genzyme (Cambridge, MA, USA), Nitrogen (Carlsbad, CA, USA), and a host of other test makers, according to a report from healthcare market research publisher Kalorama Information (New York, NY, USA). The report noted that ISH has performed better than other technologies that were predicted to dominate the industry.

"ISH is carving out a growing market share because of its usefulness for a variety of cancer markers including ER [estrogen receptor], PSA [prostate-specific antigen], EGFR [epidermal growth factor receptor], and Her-2 [human epidermal growth factor receptor 2],” said Shara Rosen, senior diagnostic analyst for Kalorama Information. "It has outperformed expectations made for it in the last decade and shown more growth so far than other celebrated areas such as microarrays and DNA assays.”

The world market for all ISH (silver, chromomeric, or fluorescent) is estimated by Kalorama Information to be US$670 million in 2009. Vendor sales are comprised mostly of individual antibodies or probes and instrumentation to automate the staining and reading of slides, along with digital imaging systems and data analysis software in high-end systems. It is these systems, which offer automated sample preparation and digital analysis instrumentation that Kalorama Information believes will continue to put ISH in a leadership position, allowing for same-day biopsy results and better patient care.

"The technology is moving from manual and operator-read to automated and digitally interpreted,” said Ms. Rosen. "ISH testing used to be qualitative and inherently subjective; resulting in significant deficiencies in the interpretation of test results, but automation has made it more relevant.”

The new automation has also allowed some movement of histology from hospital and reference laboratories to large physician practices in the United States. Digital imaging can convert entire microscope slides into high-resolution digital slides. Therefore, digitized images of an entire slide can be analyzed, stored, and remotely viewed on computer monitors located anywhere. This digital capability sets the stage for pathology telemedicine and small bench top systems for small labs and physician office laboratories as well as labs in rural areas, according to Kalorama.

Related Links:

Kalorama Information



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.